NCT06830694View on ClinicalTrials.gov

Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) with Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients from Adenocarcinoma After EGFR TKI Treatment

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

June 30, 2027

Conditions
Small Cell Carcinoma of Lung
Interventions
DRUG

Atezolizumab, Etoposide, Carboplatin, Tarlatamab

Cycle 1\~4 : Atezolizumab 1200 mg IV, carboplatin AUC 5.0 IV, Etoposide 100 mg/m2 IV Cycle 5\~ : Atezolizumab 1200 mg IV, Tarlatamab 1 or 10mg IV

All Listed Sponsors
lead

Myung-Ju Ahn

OTHER